Jagsonpal Pharmaceuticals recommends ₹4 dividend; Q4 FY26 standalone results approved.
Jagsonpal Pharmaceuticals' Board approved audited standalone financial results for Q4 FY26. The company recommended a final dividend of ₹4 per share. For FY26, total income was ₹2,769.06 million and profit before tax was ₹575.18 million. A buy-back of up to ₹400 million was also approved.
The dividend recommendation and the approval of annual results are significant for shareholders. The buy-back announcement also has a material impact.
The recommendation of a dividend and the approval of financial results with an unmodified audit opinion are positive indicators for the company.
Jagsonpal Pharmaceuticals Limited announced the outcome of its Board Meeting held on April 27, 2026. The Board approved the Audited Standalone Financial Results for the quarter and year ended March 31, 2026, along with the Independent Auditor's Review Report and a Declaration of Unmodified Opinion.
The Board recommended a final dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026. This recommendation is subject to approval at the upcoming Annual General Meeting.
The financial results indicate that for the quarter ended March 31, 2026, the company reported total income of ₹673.71 million and profit before tax of ₹117.56 million. For the full year ended March 31, 2026, total income stood at ₹2,769.06 million and profit before tax was ₹575.18 million. The net profit for the year was ₹553.61 million.
The company also disclosed details regarding an exceptional item of ₹207.9 million related to changes in employee benefits due to the New Labour Codes. Additionally, the announcement reiterated the board's approval on April 27, 2026, for a buy-back of up to 1,600,000 equity shares at ₹250 per share, for an aggregate consideration not exceeding ₹400 million, which had been approved by shareholders subsequent to the year-end on April 27, 2026.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.